GHK-Cu Gel (Copper(II)-peptide complex)
Phase 2Small molecule
GHK-Cu Gel (Copper(II)-peptide complex) is one of 21 small molecule programs targeting Wound Healing. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Wound Healing
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Nicorette
PfizerPreclinical
Zofran
NovartisPreclinical
Pitocin
RRetrophin
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Bactroban
PPadagis LLC
Preclinical
Betadine
BBecton, Dickinson and Company
Preclinical
Benadryl
PParkedale
Preclinical
Antibiotic
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHudson Biotech